Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

MH. Gilleece, A. Shimoni, M. Labopin, S. Robinson, D. Beelen, G. Socié, A. Unal, A. Ganser, A. Vitek, H. Sengeloev, I. Yakoub-Agha, E. Tholouli, E. Polge, M. Mohty, A. Nagler

. 2021 ; 11 (5) : 88. [pub] 20210512

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012445

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation registry assessed HCT outcomes by declared MRD status in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were transplanted 2006-2016 from human leukocyte antigen (HLA) matched siblings (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer in MRD NEG than MRD POS patients (18 vs. 16 months (P < 0.001). Two-year relapse rates were 24% (95% CI, 21-28) and 40% (95% CI, 34-46) in MRD NEG and MRD POS groups (P < 0.001), respectively. Leukemia-free survival (LFS) was 57% (53-61) and 46% (40-52%), respectively (P = 0.001), but there was no difference in terms of overall survival. Prognostic factors for relapse and LFS were MRD NEG status, good risk cytogenetics, and longer time from diagnosis to HCT. In-vivo T cell depletion predicted relapse.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012445
003      
CZ-PrNML
005      
20240528151043.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-021-00479-3 $2 doi
035    __
$a (PubMed)33980810
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gilleece, Maria H $u Leeds Teaching Hospitals Trust, St James's University Hospital, Leeds, LS9 7TF, United Kingdom. mgilleece@nhs.net $1 https://orcid.org/0000000303643573
245    10
$a Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT / $c MH. Gilleece, A. Shimoni, M. Labopin, S. Robinson, D. Beelen, G. Socié, A. Unal, A. Ganser, A. Vitek, H. Sengeloev, I. Yakoub-Agha, E. Tholouli, E. Polge, M. Mohty, A. Nagler
520    9_
$a Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation registry assessed HCT outcomes by declared MRD status in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were transplanted 2006-2016 from human leukocyte antigen (HLA) matched siblings (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer in MRD NEG than MRD POS patients (18 vs. 16 months (P < 0.001). Two-year relapse rates were 24% (95% CI, 21-28) and 40% (95% CI, 34-46) in MRD NEG and MRD POS groups (P < 0.001), respectively. Leukemia-free survival (LFS) was 57% (53-61) and 46% (40-52%), respectively (P = 0.001), but there was no difference in terms of overall survival. Prognostic factors for relapse and LFS were MRD NEG status, good risk cytogenetics, and longer time from diagnosis to HCT. In-vivo T cell depletion predicted relapse.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x diagnóza $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a reziduální nádor $x diagnóza $7 D018365
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a indukce remise $7 D012074
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Shimoni, Avichai $u Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel $1 https://orcid.org/0000000187826160
700    1_
$a Labopin, Myriam $u EBMT Paris study office/CEREST-TC, Paris, France
700    1_
$a Robinson, Stephen $u University Hospital Bristol NHS Foundation Trust, London, United Kingdom
700    1_
$a Beelen, Dietrich $u Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
700    1_
$a Socié, Gerard $u Hematologie/Transplantation, Hôpital St Louis, Paris, CEDEX 10, France
700    1_
$a Unal, Ali $u Kapadokya BMT Center, Kayseri, Turkey
700    1_
$a Ganser, Arnold $u Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
700    1_
$a Vitek, Antonin $u Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Sengeloev, Henrik $u Department of Haematology, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, LIRIC, INSER U995, Université de Lille, Lille, France $1 https://orcid.org/0000000345248782
700    1_
$a Tholouli, Eleni $u Manchester Royal Infirmary, Manchester, United Kingdom
700    1_
$a Polge, Emmanuelle $u Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation Paris Study Office/European Center for Biostatistical and Epidemiological Evaluation in Hematopoietic Cell Therapy (CEREST-TC), Paris, France
700    1_
$a Mohty, Mohamad $u Hôpital Saint Antoine, INSERM UMR 938, Paris, France; Université Pierre et Marie Curie, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
700    1_
$a Nagler, Arnon $u Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 11, č. 5 (2021), s. 88
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33980810 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20240528151040 $b ABA008
999    __
$a ok $b bmc $g 1789864 $s 1163646
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 5 $d 88 $e 20210512 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace